WO2013035861A1 - Procede de determination du risque de degenerescence maculaire liee a l'age, paire d'amorces, sonde, kit de diagnostic de degenerescence maculaire liee a l'age, agent therapeutique pour degenerescence maculaire liee a l'age, et procede de criblage pour agent therapeutique pour degenerescence maculaire liee a l'age - Google Patents

Procede de determination du risque de degenerescence maculaire liee a l'age, paire d'amorces, sonde, kit de diagnostic de degenerescence maculaire liee a l'age, agent therapeutique pour degenerescence maculaire liee a l'age, et procede de criblage pour agent therapeutique pour degenerescence maculaire liee a l'age Download PDF

Info

Publication number
WO2013035861A1
WO2013035861A1 PCT/JP2012/072974 JP2012072974W WO2013035861A1 WO 2013035861 A1 WO2013035861 A1 WO 2013035861A1 JP 2012072974 W JP2012072974 W JP 2012072974W WO 2013035861 A1 WO2013035861 A1 WO 2013035861A1
Authority
WO
WIPO (PCT)
Prior art keywords
age
macular degeneration
related macular
gene
amd
Prior art date
Application number
PCT/JP2012/072974
Other languages
English (en)
Japanese (ja)
Inventor
達朗 石橋
充明 久保
荒川　聡
Original Assignee
国立大学法人九州大学
独立行政法人理化学研究所
学校法人日本医科大学
学校法人日本大学
学校法人 岩手医科大学
一般社団法人徳洲会
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人九州大学, 独立行政法人理化学研究所, 学校法人日本医科大学, 学校法人日本大学, 学校法人 岩手医科大学, 一般社団法人徳洲会 filed Critical 国立大学法人九州大学
Publication of WO2013035861A1 publication Critical patent/WO2013035861A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de détermination du risque de dégénérescence maculaire liée à l'âge comprenant une étape consistant à déterminer le type de la 238ème base de l'extrémité-5' à l'extrémité-3' du gène LOC389641 contenu dans l'échantillon d'un sujet. S'il s'avère que le type de la base susmentionnée est thymine dans l'étape susmentionnée, le sujet est alors déclaré avoir un risque de dégénérescence maculaire liée à l'âge, et s'il s'avère que le type de la base est guanine lors de l'étape, le sujet est alors déclaré ne pas avoir de risque de dégénérescence maculaire liée à l'âge.　
PCT/JP2012/072974 2011-09-08 2012-09-07 Procede de determination du risque de degenerescence maculaire liee a l'age, paire d'amorces, sonde, kit de diagnostic de degenerescence maculaire liee a l'age, agent therapeutique pour degenerescence maculaire liee a l'age, et procede de criblage pour agent therapeutique pour degenerescence maculaire liee a l'age WO2013035861A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-196583 2011-09-08
JP2011196583 2011-09-08

Publications (1)

Publication Number Publication Date
WO2013035861A1 true WO2013035861A1 (fr) 2013-03-14

Family

ID=47832300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/072974 WO2013035861A1 (fr) 2011-09-08 2012-09-07 Procede de determination du risque de degenerescence maculaire liee a l'age, paire d'amorces, sonde, kit de diagnostic de degenerescence maculaire liee a l'age, agent therapeutique pour degenerescence maculaire liee a l'age, et procede de criblage pour agent therapeutique pour degenerescence maculaire liee a l'age

Country Status (1)

Country Link
WO (1) WO2013035861A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009027972A (ja) * 2007-07-26 2009-02-12 Nipro Corp 加齢黄斑変性症の発症リスクの予測方法
WO2012082912A2 (fr) * 2010-12-14 2012-06-21 Tufts Medical Center, Inc. Marqueurs associés à la dégénérescence maculaire liée à l'âge et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009027972A (ja) * 2007-07-26 2009-02-12 Nipro Corp 加齢黄斑変性症の発症リスクの予測方法
WO2012082912A2 (fr) * 2010-12-14 2012-06-21 Tufts Medical Center, Inc. Marqueurs associés à la dégénérescence maculaire liée à l'âge et leurs utilisations

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ARAKAWA S. ET AL.: "Genome-wide association study identifies two susceptibility loci for exudative age-related macular degeneration in the Japanese population", NATURE GENETICS, vol. 43, no. 10, 11 September 2011 (2011-09-11), pages 1001 - 1004 *
GUAN B. ET AL.: "Evidence that the human death receptor 4 is regulated by activator protein 1", ONCOGENE, vol. 21, 2002, pages 3121 - 3129 *
KLEIN R. J. ET AL.: "Complement Factor H Polymorphism in Age-Related Macular Degeneration", SCIENCE, vol. 308, 2005, pages 385 - 389 *
KUNIKO HORIE: "AMD no Risk Factor", PHARMA MEDICA, vol. 28, no. 12, 2010, pages 27 - 31 *
KUNIKO INOUE (HORIE) ET AL.: "Morateki Idenshi Tagata Kaiseki to Genome Joho ni Motozuku Karei Ohan Hensei Gen'in Idenshi no Kaimei to Kino Kaiseki", JOURNAL OF SAITAMA MEDICAL UNIVERSITY, vol. 35, no. 1, 2008, pages 42 - 45 *
RIVERA A. ET AL.: "Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk", HUMAN MOLECULAR GENETICS, vol. 14, no. 21, 2005, pages 3227 - 3236 *
SATOSHI ARAKAWA ET AL.: "17. Genome-wide Kanren Kaiseki ni yoru Nipponjin deno Shinshutsugata Karei Ohan Hensei no Kanjusei Idenshi o Dotei", MOMAKU MYAKURAKUMAKU ? SHISHINKEI ISHUKUSHO NI KANSURU CHOSA KENKYU HEISEI 23 NENDO SOKATSU - BUNTAN KENKYU HOKOKUSHO, March 2012 (2012-03-01), pages 60 - 62 *

Similar Documents

Publication Publication Date Title
US8053190B2 (en) Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26
WO2015073707A1 (fr) Procédés de traitement d'une insuffisance cardiaque avec des agonistes de récepteur 2 d'hypocrétine
KR20100020960A (ko) 자궁내막증과 연관된 유전자 마커 및 이의 용도
Liu et al. Copy number variations in candidate genes in neovascular age-related macular degeneration
KR20070048645A (ko) 상피 성장 인자 수용체 유전자 프로모터에 있어서의 다형성
US20200239958A1 (en) Methods of predicting the development of complement-mediated disease
EP2393939B1 (fr) Marqueur snp de risque du cancer du sein et des ovaires
US20030170674A1 (en) Nitric oxide synthase gene diagnostic polymorphisms
JP2008525000A (ja) 統合失調症及び関連障害を治療するための組成物及び方法
US20220349008A1 (en) Novel genetic markers for postural orthostatic tachycardia syndrome (pots) and methods of use thereof for diagnosis and treatment of the same
JP2022187310A (ja) 膵がん化学療法における副作用発生リスクの予測を補助する方法
WO2013035861A1 (fr) Procede de determination du risque de degenerescence maculaire liee a l'age, paire d'amorces, sonde, kit de diagnostic de degenerescence maculaire liee a l'age, agent therapeutique pour degenerescence maculaire liee a l'age, et procede de criblage pour agent therapeutique pour degenerescence maculaire liee a l'age
US20150211066A1 (en) Methods and Compositions for Correlating Genetic Markers with Sudden Cardiac Death Risk
US8236497B2 (en) Methods of diagnosing cardiovascular disease
US20140045717A1 (en) Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism
KR101617612B1 (ko) 한국인의 고혈압 예측용 ｓｎｐ 마커
CN105765077B (zh) 测定抗甲状腺药物诱导的粒细胞缺乏症风险的检测方法以及测定用试剂盒
KR101092580B1 (ko) 위암 감수성 예측용 ｖｃａｎ 다형성 마커 및 이를 이용한위암 감수성 예측 방법
KR101304535B1 (ko) Ｋｌｏｔｈｏ 유전자의 단일염기다형을 이용한 심혈관계 질환 예측 방법
EP2233585A1 (fr) Procédé d'essai pour le diabète de type 2 à l'aide d'un polymorphisme de gène
JP6082693B2 (ja) 喫煙感受性加齢黄斑変性易罹患性の判定方法及び判定キット
KR20150092937A (ko) 한국인의 고혈압 예측용 ｓｎｐ 마커
WO2010014000A1 (fr) Marqueurs de prédisposition pour la sclérose en plaques
WO2006125513A1 (fr) Association genetique de polymorphismes dans le gene atf6-alpha avec des phenotypes de resistance a l'insuline
Hu et al. Schizophrenia susceptibility genes on chromosome 13q32

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12830078

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12830078

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP